Literature DB >> 20706786

The incidence of low eGFR and proteinuria in a large tertiary referral lipid clinic.

Joseph B Davies1, Martin A Crook, Anthony S Wierzbicki, David J Goldsmith.   

Abstract

INTRODUCTION: The prevalence of chronic kidney disease (CKD) stages 3 to 5, defined as eGFR <60 ml/min/1.73 m(2) for more than three months, in the United Kingdom (UK) is 8%. We investigated the incidence of low eGFR and proteinuria in patients attending our large tertiary referral lipid clinic in 2008.
METHODS: In 2008, 1,283 patients were seen, of which 1,029 had complete serum lipid and renal profiles. Estimated glomerular filtration rate (eGFR) was calculated for these patients using the 4-variable MDRD formula. The prevalence of low eGFR (eGFR < 60 ml/min/1.73 m(2)) and proteinuria (albumin/creatinine ratio >2.4 mg/mmol or urinary protein excretion >0.06 g/l) was calculated.
RESULTS: The prevalence of low eGFR and proteinuria was 11.2 and 19.4%, respectively. The percentage of patients with serum lipid levels within the target range suggested by international guidelines was lower among those with low eGFR and proteinuria than in the entire study population, despite similar proportions being treated with statins across all groups.
CONCLUSIONS: The prevalences of low eGFR and proteinuria in a group of 1,029 dyslipidaemic patients attending a large tertiary referral lipid clinic were 11.18 and 19.42%, respectively. These levels are much higher than in the general UK population.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20706786     DOI: 10.1007/s11255-010-9819-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  12 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Jane Marsh; Lesley A Stevens; John W Kusek; Frederick Van Lente
Journal:  Clin Chem       Date:  2007-03-01       Impact factor: 8.327

4.  The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

Authors:  Martin Landray; Colin Baigent; Craig Leaper; Dwomoa Adu; Paul Altmann; Jane Armitage; Simon Ball; Alex Baxter; Lisa Blackwell; Hugh S Cairns; Sue Carr; Rory Collins; Karen Kourellias; Mary Rogerson; John E Scoble; Charles R V Tomson; Graham Warwick; David C Wheeler
Journal:  Am J Kidney Dis       Date:  2006-03       Impact factor: 8.860

5.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

6.  Effects of hypertension and dyslipidemia on the decline in renal function.

Authors:  M Mänttäri; E Tiula; T Alikoski; V Manninen
Journal:  Hypertension       Date:  1995-10       Impact factor: 10.190

7.  Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

Authors:  P Muntner; J Coresh; J C Smith; J Eckfeldt; M J Klag
Journal:  Kidney Int       Date:  2000-07       Impact factor: 10.612

8.  Prevalence of chronic kidney disease in the United States.

Authors:  Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

9.  Predictors of new-onset kidney disease in a community-based population.

Authors:  Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy
Journal:  JAMA       Date:  2004-02-18       Impact factor: 56.272

Review 10.  Study of Heart and Renal Protection (SHARP).

Authors:  Colin Baigent; Martin Landry
Journal:  Kidney Int Suppl       Date:  2003-05       Impact factor: 10.545

View more
  1 in total

Review 1.  Evidence-based statin prescription for cardiovascular protection in renal impairment.

Authors:  Fabio Fabbian; Alfredo De Giorgi; Marco Pala; Ruana Tiseo; Roberto Manfredini; Francesco Portaluppi
Journal:  Clin Exp Nephrol       Date:  2011-05-10       Impact factor: 2.801

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.